Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer

Clinical Cancer Research

Volumn 22, Issue 9, 2016, Pages 2250-2260

  Yang, Wei ^a   Hosford, Sarah R ^a   Dillon, Lloye M ^a   Shee, Kevin ^a   Liu, Stephanie C ^a   Bean, Jennifer R ^a   Salphati, Laurent ^b   Pang, Jodie ^b   Zhang, Xiaolin ^b   Nannini, Michelle A ^c   Demidenko, Eugene ^a   Bates, Darcy ^a   Lewis, Lionel D ^a   Marotti, Jonathan D ^a   Eastman, Alan R ^a   Miller, Todd W ^a,d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Departmentof Drug Metabolism and Pharmacokinetics ^*  (United States)

^c GENENTECH INC   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; ESTRADIOL; INDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; ELIMINATION HALF-LIFE; ENZYME INHIBITION; ENZYME REACTIVATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MCF-7 CELL LINE; METABOLISM; MUTATION; NONOBESE DIABETIC MOUSE; THERAPEUTIC INDEX; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INDAZOLES; MCF-7 CELLS; MICE; MICE, INBRED NOD; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SULFONAMIDES; THERAPEUTIC INDEX;

EID: 84968538982     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2276     Document Type: Article

References (41)

1. Ferlay JS, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Internat J Cancer 2010: 2893-917.
2. Early Breast Cancer Trialists' Collaborative G. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378: 771-84.
3. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
4. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452-61.
5. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
6. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
7. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1:338-51.
8. Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, etal. LossofPhosphatase and Tensinhomologuedeleted onchromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009;69:4192-201.
9. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
10. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
11. Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009;15:7266-76.
12. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
13. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 2008;118: 3065-74.
14. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2014;32:1202-9.
15. Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER? , aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results. Presented at the San Antonio Breast Cancer Symposium, December 10, 2014. 2014:Abstract S2-02.
16. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
17. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-inhuman phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015;21:77-86.
18. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, et al. Phase I doseescalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014;32:670-81.
19. Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol 2015;11:525-531.
20. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010;2:16ra7.
21. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-93.
22. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, et al. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol 2012;23: 1023-9.
23. Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov 2014;4:538-45.
24. Helbig G, Stella-Holowiecka B, Majewski M, Calbecka M, Gajkowska J, Klimkiewicz R, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008;141:200-4.
25. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncol 2011;13:1364-9.
26. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
27. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17: 1514-20.
28. Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, et al. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/ AKT and MEK/ERK signaling in breast cancer. Oncogene 2015;34: 3968-76.
29. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010;38:1436-42.
30. Demidenko E. The assessment of tumour response to treatment. Appl Stat 2006;55:365-77.
31. Demidenko E. Three endpoints of in vivo tumour radiobiology and their statistical estimation. Internat J Radiat Biol 2010;86:164-73.
32. Demidenko E. Mixed models: Theory and applications with R. 2nd ed. New York: Wiley; 2013.
33. Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
34. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011;1:352-65.
35. Coppola JM, Ross BD, Rehemtulla A. Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res 2008;14: 2492-501.
36. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci Translational Med 2013;5: 196ra99.
37. Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer 2013;13:604.
38. Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, et al. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat 2015;149:69-79.
39. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012;109:2718-23.
40. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res 2014;74:3146-56.
41. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-65.